The expanding incretin universe: from basic biology to clinical translation

Drucker, Daniel J., Holst, Jens J.·2023·Diabetologia
DOI 10.1007/s00125-023-05906-7

Cited by (243)

Items 101–200 of 243

  1. Activation of Gs signaling in mouse enteroendocrine K cells greatly improves obesity- and diabetes-related metabolic deficits
    Antwi‐Boasiako Oteng, Liu Liu, Yinghong Cui, Oksana Gavrilova, Huiyan Lü, Min Chen, Lee Scott Weinstein, Jonathan E. Campbell, Jo Edward Lewis, Fiona Mary Gribble et al. · 2024 · Journal of Clinical Investigation
  2. The Potential Mechanism of Remission in Type 2 Diabetes Mellitus After Vertical Sleeve Gastrectomy
    Rongfei Wang, Salamu Mijiti, Qilin Xu, Yile Liu, Chaolun Deng, Jiangtao Huang, Abudoukeyimu Yasheng, Yunping Tian, Yanlong Cao, Yonghui Su · 2024 · Obesity Surgery
  3. Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease
    Guangyi Xu, Yu An, Yage Du, Zhaoming Cao, Jie Zheng, Jingya Wang, Tingyi Li, Xin Gen Lei, Yanhui Lu · 2025 · iMetaOmics.
  4. Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
    Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu · 2025 · Clinical Pharmacology & Therapeutics
  5. Advantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide‐Treated and Pair‐Fed Rats
    Suyeun Byun, Morgan R. Sotzen, Mya A. Knappenberger, Madison T. Bento, Mohammed Asker, Doris I. Olekanma, Karolina Patrycja Skibicka · 2025 · Comprehensive physiology
  6. Lipid regulation of the glucagon receptor family
    Affiong I Oqua, Yusman Manchanda, Emma Rose McGlone, Ben J. Jones, Sarah L. Rouse, Alejandra Tomás · 2024 · Journal of Endocrinology
  7. Anekomochi glutinous rice provides low postprandial glycemic response by enhanced insulin action via GLP-1 release and vagal afferents activation
    Kento Ohbayashi, Yudai Sugiyama, Taichi Nohmi, Kazusa Nishimura, Tetsuya Nakazaki, Yoichiro Sato, Takehiro Masumura, Yusaku Iwasaki · 2024 · The Journal of Physiological Sciences
  8. Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing
    Wei Zhang, Bharathi Natarajan, Palanisamy Kannan, Rostislav Medlín, Laurent Nicolaï, Michal Procházka, Jan Minar, Palaniappan Subramanian · 2024 · Biosensors and Bioelectronics
  9. On the front lines of cardiovascular-kidney-metabolic syndrome: Review of GLP-1 and Dual GLP-1/GIP receptor agonists in CV and kidney health
    Lavinia Salama, Levi Sinn · 2025 · American Journal of Health-System Pharmacy
  10. The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes
    Ioannis Avgerinos, Panagiota Kakotrichi, Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας · 2024 · Expert Opinion on Drug Discovery
  11. Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
    Emir M. Muzurović, Martin Haluzı́k, Ludek Horváth, Bogdan Vlacho, Dı́dac Mauricio · 2025 · Current Pharmaceutical Design
  12. Molecular mimicry: ecology, evolution, and applications of doppelgänger peptides
    Thomas Lund Koch, Samuel D. Robinson, Helena Safavi-­Hemami · 2025 · Trends in Biochemical Sciences
  13. Immune and Vascular Function in Cardiometabolic Disorders: Interplay With Sex Differences and Impact on Incretin Therapy
    Anirudh Subramanian Muralikrishnan, Valentina Biasin, Diana Zabini, Elena Osto · 2025 · Acta Physiologica
  14. The Effects of Obesity and Weight Loss Interventions on Bone Health: A Narrative Review
    Andrea Palermo, Elena A. Tsourdi, Maria P. Yavropoulou, Anda Mihaela Naciu, Gaia Tabacco, Polyzois Makras, Julien Paccou, Athanasios D. Anastasilakis · 2025 · Current Diabetes Reports
  15. Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes
    Riccardo Candido, Barbara Toffoli, Gabriele Baccichetto, Francesca Marchese, Silvia Carpenè, Sara Gaiotti, Bruno Fabris, Stella Bernardi · 2025 · Acta Diabetologica
  16. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review
    Marie‐Laure Laroche, Hélène Geniaux, Manon Jardou · 2026 · European Journal of Clinical Pharmacology
  17. Hormone imbalances detected in study participants with pre-diabetes in a Durban-based clinical setting, South Africa
    Aubrey Mbulelo Sosibo, Nomusa Christina Mzimela, Phikelelani Siphosethu Ngubane, Andile Khathi · 2024 · International Journal of Diabetes in Developing Countries
  18. GLP-1R signaling does not modify the severity of experimental graft versus host disease
    Bernardo Yusta, Chi Kin Wong, Dianne Matthews, Jacqueline A. Koehler, Laurie L. Baggio, K.W. Annie Bang, Daniel J. Drucker · 2025 · Molecular Metabolism
  19. A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues
    Kathleen M. Sicinski, Damla Sürmeli, Jasper Du, Venkata S. Raman, Vittorio Montanari, Minhee Lee, Benjamin N. Harwood, Alan S. Kopin, Martin Beinborn, Krishna Kumar · 2024 · Journal of Medicinal Chemistry
  20. Gut Hormones in Heart Failure
    Tania Deis, Jens Peter Goetze, Caroline Kistorp, Finn Gustafsson · 2024 · Circulation Heart Failure
  21. Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
    Aly M. Abdelrahman, Alaa S. Awad, Irtiza Hasan, Emaad M. Abdel‐Rahman · 2024 · Journal of Clinical Medicine
  22. Cell-specific DNA methylation in human alpha and beta cells regulates gene expression in type 2 diabetes
    Jones K. Ofori, Sabrina Ruhrmann, Axel Lindström, Alexander Perfilyev, Melina Martin, Alexandros Karagiannopoulos, Lucia Scisciola, Katja Kost, Josefine Jönsson, Åsa Nilsson et al. · 2026 · Nature Metabolism
  23. A sympathetic brake on gut GLP-1 release
    Antonio J. López-Gambero, Victor Jouque, Daniela Cota · 2024 · Neuron
  24. Prolonged Activation of the GLP-1 Receptor via Covalent Capture
    Özge Ünsal, Z. Selin Bacaksiz, Vladislav Khamraev, Vittorio Montanari, Martin Beinborn, Krishna Kumar · 2024 · ACS Chemical Biology
  25. Phenotypes of Obesity Hypoventilation Syndrome: Characteristics and Outcomes
    Juan F. Masa, Victor R. Ramírez-Molina, Celia De Dios Calama · 2025 · Seminars in Respiratory and Critical Care Medicine
  26. Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP ‐ 1R / GIPR dual agonist, HISHS ‐2001
    Yusman Manchanda, Ben J. Jones, Gaëlle Carrat, Zenouska Ramchunder, Piero Marchetti, Isabelle Leclerc, Rajamannar Thennati, VINOD S. BURADE, Muthukumaran Natarajan, Pradeep Kumar Shahi et al. · 2025 · Diabetes Obesity and Metabolism
  27. Anti-Incretin Gut Features Induced by Feed Supplementation with Alpha-Amylase: Studies on EPI Pigs
    Kateryna Goncharova Pierzynowska, Piotr Wychowański, Kamil Zaworski, Jarosław Woliński, Janine Donaldson, Stefan Grzegorz Pierzynowski · 2023 · International Journal of Molecular Sciences
  28. Discordance between gut-derived appetite hormones and energy intake in humans
    Aaron Hengist, Christina M. Sciarrillo, Juen Guo, Mary F. Walter, Kevin D. Hall · 2023 · medRxiv
  29. Incretins: turning the venom into the antidote
    Anna Krook, Hindrik Mulder · 2023 · Diabetologia
  30. Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells
    Affiong I Oqua, Kin Chao, Liliane El Eid, Lisa Casteller, Billy P Baxter, Alba Miguéns‐Gómez, Sebastian Barg, Ben J. Jones, Jorge Bernardino de la Serna, Sarah L. Rouse et al. · 2024 · eLife
  31. Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells
    Affiong I Oqua, Kin Chao, Liliane El Eid, Lisa Casteller, Alba Miguéns, Sebastian Barg, Ben J. Jones, Jorge Bernardino de la Serna, Sarah L. Rouse, Alejandra Tomás · 2024 · eLife
  32. Incretins and Development of Incretin‐based Therapeutics
    Nan Zheng, Xiao‐xuan Su, Shengping Zhang, Weijun Shen · 2025 · Peptide Science
  33. Sleep and Circadian Effects on the Incretin System
    Robin K. Yuan, Kirsi‐Marja Zitting · 2025 · Current Sleep Medicine Reports
  34. Dynamic multi-omics profiling of islet and gut hormonal secretion and peripheral crosstalk in response to various nutrient loads
    Jiachen Wang, Lin Liu, Hechun Liu, Yu Qian, Sijie Zhang, Shuai Zheng, Hemin Jiang, Yue Zhou, Xiaoliang Cheng, Qi Fu et al. · 2025 · Cell Reports Medicine
  35. Can muscle avert GLP1R weight plateau and regain?
    Dongdong Wang, Andre Djalalvandi, Christina T. Saed, Katherine Mary Morrison, Gregory R. Steinberg · 2025 · Cell Reports Medicine
  36. Antimony induces oxidative stress to impair enteroendocrine cells and disrupt glucose homeostasis
    Lanfei Jin, Longtao Zhu, Chengdong Wu, Weiqiong Jin, Ke Liu, Junxuan Peng, Xin Xu, Xiaolong Ge, Ying Zhu, Xiaole Sheng et al. · 2025 · Journal of Hazardous Materials
  37. Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics
    Bashaier Al‐Zaid, Jehad Ahmed Abubaker, Anwar Mohammad, M. Abufarha, Fahd Al‐Mulla, Suleiman Al‐Sabah · 2026 · European Journal of Pharmacology
  38. Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases
    Derin Karacabeyli, Diane V. Lacaille · 2026 · Rheumatology
  39. The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
    Akihiro Hamasaki, Norio Harada, Atsushi Muraoka, Shunsuke Yamane, Erina Joo, Kazuyo Suzuki, Nobuya Inagaki · 2024 · Frontiers in Endocrinology
  40. Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes
    Jens Juul Holst · 2024 · The Journal of Physiology
  41. Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
    Zhimin Xu, Song Wen, Meiyuan Dong, Ligang Zhou · 2024 · Diabetes Obesity and Metabolism
  42. The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
    Bashaier Al‐Zaid, Suleiman Al‐Sabah · 2025 · Frontiers in Pharmacology
  43. Combined minimally invasive vagal cranial nerve and trigeminocervical complex peripheral nerve stimulation produces prolonged improvement of severe painful peripheral neuropathy and hyperglycemia in type 2 diabetes
    Peter S. Staats, Alyssa Staats, Brittny Mikhaiel, Jason Chen, Éric Azabou, Claire-Marie Rangon · 2025 · Frontiers in Neuroscience
  44. Extracellular vesicle signature is associated with cardio-metabolic improvement after bariatric surgery
    Jacopo Burrello, Mary Gonzalez Melo, Amy Taheri, Marisa Nagler, Lorenzo Airale, Alessio Burrello, Jessica Goi, Marko Kraljević, Tarik Delko, Elisa Dietrich et al. · 2025 · European Journal of Preventive Cardiology
  45. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
    Jingjing Zhu, John P.H. Wilding · 2023 · Current Atherosclerosis Reports
  46. Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in Humans
    Gianfranco Di Giuseppe, Giulia Gliozzo, Gea Ciccarelli, Lorenzo Carciero, Michela Brunetti, Laura Soldovieri, Giuseppe Quero, Francesca Cinti, Enrico Celestino Nista, Sara Sofia De Lucia et al. · 2025 · The Journal of Clinical Endocrinology & Metabolism
  47. Dorothy Hodgkin lecture 2023: The enteroendocrine system—Sensors in your guts
    Frank M. Reimann · 2023 · Diabetic Medicine
  48. Stearic acid-modified hexavanadate vesicles loaded with hydroxy fatty acid esters synergistically improve obesity-related metabolic disorders and inflammation
    Pengyu Wu, Pengcheng Cui, Yingying Wang, Kun Chen · 2025 · Polyoxometalates
  49. Increased cholesterol interactions in the active conformational state of the glucagon-like peptide-1 receptor
    Amit Naglekar, Amitabha Chattopadhyay, Durba Sengupta · 2025 · Biophysical Journal
  50. The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population
    Vasileios Petrakis, Petros I. Rafailidis, Maria I. Panopoulou, Theocharis G. Konstantinidis, Andreas G. Tsantes, Nikoleta Babaka, Dimitrios Papazoglou, Periklis Panagopoulos · 2025 · Experimental and Clinical Endocrinology & Diabetes
  51. Circulating levels of gut hormones in anorexia nervosa before and after short-term weight restoration
    Theresa Kolb, Louisa Licht, Friederike I. Tam, Evelina Marie Stender, Michaela Ohme, Alessandra Borsini, Stefan Ehrlich, Nikolaos Perakakis · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  52. The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism
    Angyi Lin, Hideki Kitaura, Fumitoshi Ohori, Aseel Marahleh, Jinghan Ma, Ziqiu Fan, Kohei Narita, Kou Murakami, HIROYASU KANETAKA · 2026 · International Journal of Molecular Sciences
  53. Endogenous GIP signaling is indispensable for DPP ‐4 inhibitor‐mediated metabolic control in mice
    Saki Kubota‐Okamoto, Sodai Kubota, Hiromi Tsuchida, Yanyan Liu, Seiya Banno, Toshinori Imaizumi, Taro Fujisawa, Yoshihiro Takahashi, T. Kato, Yukio Horikawa et al. · 2026 · Journal of Diabetes Investigation
  54. Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease
    Domenico Tricò, Tongzhi Wu, Noemi Cimbalo, Martina Chiriacò, Cong Xie, Luca Sacchetta, Lorenzo Nesti, Simone Gallo, Lorenza Santoni, Maria Chiara Masoni et al. · 2026 · Diabetologia
  55. From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
    Jens Juul Holst · 2026 · Biological Psychiatry
  56. Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
    Julia Bijoch · 2026 · Journal of Clinical Medicine
  57. „Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
    Dirk Raddatz · 2023 · Journal für Gastroenterologische und Hepatologische Erkrankungen
  58. Anti-Inflammatory Effects of Glucagon-Like Peptide-1 Receptor Agonists via the Neuroimmune Axis
    Susanna Fang, Chi Kin Wong · 2024 · DNA and Cell Biology
  59. Incretin-based weight loss therapies and heart failure with preserved ejection fraction: guideline impactful results, but mechanisms unclear
    Katarzyna A. Stefanska, Naveed A. Sattar · 2025 · Cardiovascular Research
  60. Effects of Weight-lowering Medications in People With Obesity and Rheumatic Diseases
    Derin Karacabeyli, Diane V. Lacaille · 2025 · Current Treatment Options in Rheumatology
  61. Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model
    Xun Sun, Yuexi Yin, Min Song, Brian A. Droz, YANZHU LIN, Kristen N Beaty, Baohua Zhou, Hyun Cheol Roh, Jonathan Matthew Wilson, Paul Cain et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  62. The role of incretins in gestational diabetes: a case-control study on the impact of obesity
    Engin Yurtçu, Betül Keyif, Gamze Yılmaz, Selçuk Erkılınç, Hatice Akkaya, Ayse Seval Ozgu-Erdinc · 2024 · Diabetology & Metabolic Syndrome
  63. The relationship between cholecystokinin and gastrin
    Jens Frederik Rehfeld · 2025 · Elsevier eBooks
  64. Teratogenic risks of treated and untreated maternal obesity
    Robert E. Jones, Chloe Zera · 2025 · Seminars in Perinatology
  65. Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions
    Radica Z. Alicic, Joshua J. Neumiller · 2025 · Cardiology Clinics
  66. GLP-1 Receptor Agonist Use in Pregnancy
    Irena Druce · 2025 · Canadian Diabetes & Endocrinology Today
  67. Food and the brain: Neural and endocrine control of feeding, metabolism, and reproduction
    Naira da Silva Mansano, Calvin V. Lieu, Alfonso B. Abizaid · 2025 · Journal of Neuroendocrinology
  68. Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes
    Minoru Takemoto, Bo‐Shi Zhang, Aiko Hayashi, Hiroki Yamagata, Yoich Yoshida, Masaya Koshizaka, Shunichiro Onishi, Masaya Yamaga, Tomohiko Yoshida, Takahide Hashimoto et al. · 2025 · Scientific Reports
  69. Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
    Yang Liu, Xiaokun Gang, Xinming Liu, Wei Jiang, Yuqi Yang, Guixia Wang · 2025 · Frontiers in Endocrinology
  70. Insights into the mechanisms of body weight control
    Sandra Pereira · 2025 · AJP Advances in Physiology Education
  71. Loss of GLP-2R signaling in Glp2r−/− mice increases the long-term severity of graft versus host disease
    Bernardo Yusta, Chi Kin Wong, Dianne Matthews, Jacqueline A. Koehler, Laurie L. Baggio, Daniel J. Drucker · 2025 · Molecular Metabolism
  72. Toxins in disguise: Neuropeptide mimicry across animal venoms
    Thomas Lund Koch, Helena Safavi-­Hemami · 2026 · General and Comparative Endocrinology
  73. Gestational Arsenic Exposure Induces Metabolic Dysfunction-Associated Fatty Liver Disease–like Phenotypes in Middle-Aged Offspring
    Qian-Qun Yang, Qing-Hua Qian, Wen Zhang, Ya-ping Song, Qing-Yuan Huang, Xue Lu, Tao Wang, Yichao Huang, De‐Xiang Xu · 2026 · Environment & Health
  74. Cross-Organ Neuroimmunology of Behavior
    Xuanming Guo, Scott J. Russo · 2026 · Annual Review of Immunology
  75. Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
    Andrew G. Renehan, Michaël Pollak · 2026 · Cancer Prevention Research
  76. Tirzepatide-associated interstitial kidney injury
    Mohamed Eldib, Vaidehi Alkeshbhai Mendpara, Leal Herlitz, Paloma Rodríguez Álvarez, Jagmeet S. Dhingra, Leila Zeinab Khan · 2026 · JCEM Case Reports
  77. Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure
    Jiayan Xie, Yujing Yang, Wanting Chen, Lu Wang (45927), Siying Weng, Qiang Lyu, Gang Cao · 2026 · Current Obesity Reports
  78. Computational discovery of fenugreek–paitan–turmeric (FPT) bioactive compounds targeting SGLT2 and DPP-4 for glucose homeostasis regulation
    Gita Sekar Prihanti, Anung Putri Illahika, Noviana D. Lestari · 2026 · Journal of Taibah University Medical Sciences
  79. Contractile effects of dulaglutide in the human atrium
    Joachim Neumann, Milena Jarikova, Britt Hofmann, Uwe Kirchhefer, Ulrich Gergs · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  80. Contractile effects of albiglutide in the human and mouse atrium
    Neumann Jn, Milena Jarikova, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs · 2026 · Frontiers in Endocrinology
  81. Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis
    Abdur Rafay Bilal, Maryam Sajid, S M Washaqul Arfin, Abdur Raheem Bilal, Hateem Gaba, Shaheer Qureshi, Muhammad Zubair Farooq, Muhammad Haris Inam, Hasibullah Aminpoor, Saad Ahmed Waqas · 2026 · Journal of Diabetes & Metabolic Disorders
  82. Kardiovaskuläre Protektion durch Rezeptoragonisten des glukagonähnlichen Peptids 1
    Berkan Kurt, Florian Kahles · 2023 · Die Diabetologie
  83. Unlocking Therapeutic Synergy: Tailoring Drugs for Comorbidities such as Depression and Diabetes through Identical Molecular Targets in Different Cell Types
    Thierry Coppola, Guillaume Daziano, Ilona Legroux, Sophie Béraud-Dufour, Nicolas Blondeau, Patricia Lebrun · 2023 · Cells
  84. Obésité : entre pléthore thérapeutique et questionnements nécessaires
    S. Halimi · 2024 · Médecine des Maladies Métaboliques
  85. GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
    Marika Dębik, Łukasz Szydłowski, Klaudia Żurowska, Artur Bednarski, Aleksandra Krużel, Seweryn Ziajor, Piotr Sajdak, Justyna Małgorzata Tomasik, Marcel Stodolak, Kamil Kłos · 2024 · Journal of Education Health and Sport
  86. Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐ O trial
    Hertzel C. Gerstein, Mu Yang, Shun Fu Lee, Kelley R. Branch, Stefano Del Prato, Carolyn S.P. Lam, Renato D. Lópes, Richard E. Pratley, Julio Rosenstock, Naveed A. Sattar · 2024 · Diabetes Obesity and Metabolism
  87. Diabetes Mellitus and the Risk of Carcinogenesis: An Interdisciplinary Approach
    Halina Tkaczenko, Piotr Kamiński, Natalia Kurhaluk · 2024 · Interdisciplinary cancer research
  88. Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure
    Cole E. Hansell, Hamam Aneis, Georgios D. Kitsios, William Bain, Yanwu Zhao, Tomeka L. Suber, John W. Evankovich, Lokesh Sharma, Sadeesh Kumar Ramakrishnan, Niall T. Prendergast et al. · 2025 · Critical Care Explorations
  89. Impact of Glucagon-Like Peptide-1 Analogues in the Treatment of Obstructive Sleep Apnoea: A Pro/Con Debate
    Olga Mediano, Juan F. Masa · 2025 · Archivos de Bronconeumología
  90. Gut microbe-derived lactic acid optimizes host energy metabolism during starvation
    Jason W. Millington, Jamie Alcira Lopez, Amin M. Sajjadian, Robert J. Scheffler, Brian C. DeFelice, William Basil Ludington, Benjamin H. Good, Lucy Erin O’Brien, Kerwyn Casey Huang · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  91. Place du traitement médicamenteux dans l’obésité de l’enfant et de l’adolescent
    Marie‐Laure Frelut · 2023 · Neuropsychiatrie de l Enfance et de l Adolescence
  92. GLP-1 Secretion Induced by Dietary Proteins and Peptides, and Its Hypoglycemic and Thermic Effects
    Tohru Hira · 2024 · Nippon Eiyo Shokuryo Gakkaishi
  93. Outcomes of Type 2 Diabetes Management: One Center Experience 2015–2023
    Rudolf Chlup, Hana Zálešáková, Jiřina Gottwaldová, Michal Trefil, Jana Zapletalová, Richard Kaňa, Lada Hanáčková, Milena Bretšnajdrová, Přemysl Falt, Zdenka Polzerová · 2024 · IntechOpen eBooks
  94. Potent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors
    Tristan C. Dinsmore, Jamie Liu, Jiayuan Miao, Özge Ünsal, Damla Sürmeli, Martin Beinborn, Yu‐Shan Lin, Krishna Kumar · 2024 · Angewandte Chemie
  95. Glucagon-like peptide-1
    Darleen A. Sandoval · 2025 · Trends in Endocrinology and Metabolism
  96. D’une longue pénurie thérapeutique au triomphe des nouvelles classes d’antidiabétiques dans des maladies non métaboliques
    S. Halimi · 2025 · Médecine des Maladies Métaboliques
  97. STARTing a new path in cardiovascular prevention: Lessons from SELECT and real-world evidence on Semaglutide in obesity-driven risk
    Giuseppe Andò, Giulia Cavolina, Alessio Villari, Pierre François Sabouret, Giuseppe Musumeci · 2025 · International Journal of Cardiology
  98. Islet effects of cholecystokinin and exploitation in diabetes
    Neil Tanday, Nigel Irwin, Peter R. Flatt · 2025 · Elsevier eBooks
  99. Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells
    Affiong I Oqua, Kin Chao, Liliane El Eid, Lisa Casteller, Billy P Baxter, Alba Miguéns‐Gómez, Sebastian Barg, Ben J. Jones, Jorge Bernardino de la Serna, Sarah L. Rouse et al. · 2025 · eLife
  100. Pediatric Obesity Pharmacotherapy
    Alexandria Speakman, Farhana Ali-Geiger, Marialena Mouzaki · 2025 · Gastroenterology Clinics of North America